× Main Page Fashion Lifestyle Sport Home Travel Real Estate Business
Social Responsibility Education Innovations
Brands Lists
× Main Page Fashion Lifestyle Sport Home Travel Real Estate Business

BUSINESS - COMPANY NEWS

Ava Closes $30M Series B Funding Round and Announces 10,000th "Ava" Pregnancy

Wednesday, May 30, 2018

The Ava bracelet detects a woman's 5-day fertile window in real time

The Ava bracelet detects a woman's 5-day fertile window in real time

BUSINESS - COMPANY NEWS

Source : Ava

Facebook Share Twitter Tweet Google Plus Share

Ava, a medical technology company focused on innovations in women's reproductive health and maker of the popular cycle tracking Ava bracelet, today announced it has raised $30 million in a strategic Series B funding round. The majority of Ava's new financing came from existing investors, with prominent European VC firm btov and SVC Ltd., an investment vehicle of Credit Suisse, also joining the round.

Ava also announced today that its cycle-tracking sensor bracelet, which precisely detects the 5.3-day fertile window in a woman's cycle in real time, has officially reached a milestone of 10,000 pregnancies among users since launching in July 2016.

According to Ava Co-Founder Pascal Koenig, Ava will use the new funds for further product research and development to enhance the existing product and create new applications that empower women to take control of their reproductive health via data insights and science.

"Ava's long-term vision is to accompany women through all stages of their reproductive life by providing data-driven, clinically proven technology that will make a woman's life easier, healthier and better -- be it when they just want to understand their body, while they are trying to prevent pregnancy, trying to get pregnant, are pregnant or entering menopause," Koenig explained.

Ava continues to invest heavily in clinical trials with the University Hospital of Zurich under the direction of Prof. Brigitte Leeners to study applications of the Ava technology among women trying to get pregnant, suffering from fertility challenges, and to understand complications during pregnancy. Last year, Ava also hired its first Chief Medical Officer, renowned Bayer Schering veteran Dr. Maureen Cronin, to help shepherd the company through clinical and regulatory processes involved in new product development, particularly in the area of contraceptives.

"It's exciting to work with a company that is literally reshaping the way we think about menstrual cycles, hormones and women's health," said Prof. Leeners. "Combining the best in science, data insights and technology is not only helping to create families, but improving women's lives around the world."





LATEST POSTS
Alan Blakely is the author of several architectural photography books and publications, and he is a regular contributor to The New York Times.
I talked to Elliott Haydon, Founder and CEO of Eldon Watches, to get more information about modular watches.
Bosch solution makes electrical powertrains for delivery vehicles cheaper and more efficient.
I asked Stephanie Morales Casariego, Co-Founder of CSpace Architecture + Design, about her career, works and the basics of architectural projects.